Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Elevance Health Analyst Ratings and Price Targets | NYSE:ELV | Benzinga
Elevance Health Inc has a consensus price target of $536.25 based on the ratings of 26 analysts. The high is $631 issued by JP Morgan on May 30, 2024. The low is $434 issued by Barclays on July 9, 2025. The 3 most-recent analyst ratings were released by Barclays, Truist Securities, and RBC Capital on July 9, 2025, June 9, 2025, and June 4, 2025, respectively. With an average price target of $470.67 between Barclays, Truist Securities, and RBC Capital, there's an implied 38.18% upside for Elevance Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Truist Securities
RBC Capital
Argus Research
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Elevance Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/09/2025 | Buy Now | 27.41% | Barclays | Andrew Mok | $480 → $434 | Maintains | Overweight | Get Alert |
| 06/09/2025 | Buy Now | 46.79% | Truist Securities | David Macdonald | $510 → $500 | Maintains | Buy | Get Alert |
| 06/04/2025 | Buy Now | 40.33% | RBC Capital | Ben Hendrix | $478 → $478 | Reiterates | Outperform → Outperform | Get Alert |
| 06/02/2025 | Buy Now | 40.92% | Barclays | Andrew Mok | $522 → $480 | Maintains | Overweight | Get Alert |
| 04/25/2025 | Buy Now | 36.51% | Argus Research | David Toung | $450 → $465 | Maintains | Buy | Get Alert |
| 04/23/2025 | Buy Now | 40.33% | RBC Capital | Ben Hendrix | $478 → $478 | Reiterates | Outperform → Outperform | Get Alert |
| 04/23/2025 | Buy Now | 52.07% | Guggenheim | Jason Cassorla | $518 → $518 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2025 | Buy Now | 42.39% | Cantor Fitzgerald | Sarah James | $485 → $485 | Reiterates | Overweight → Overweight | Get Alert |
| 04/23/2025 | Buy Now | 53.25% | Barclays | Andrew Mok | $512 → $522 | Maintains | Overweight | Get Alert |
| 04/15/2025 | Buy Now | 55.3% | Baird | Michael Ha | $625 → $529 | Downgrade | Outperform → Neutral | Get Alert |
| 04/11/2025 | Buy Now | 49.73% | Truist Securities | David Macdonald | $480 → $510 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | 52.07% | Guggenheim | Jason Cassorla | → $518 | Initiates | → Buy | Get Alert |
| 04/09/2025 | Buy Now | 48.26% | Mizuho | Ann Hynes | $455 → $505 | Maintains | Outperform | Get Alert |
| 03/17/2025 | Buy Now | 32.11% | Argus Research | David Toung | → $450 | Upgrade | Hold → Buy | Get Alert |
| 01/29/2025 | Buy Now | 19.02% | Argus Research | David Toung | $405.4 → $405.4 | Reiterates | Hold → Hold | Get Alert |
| 01/28/2025 | Buy Now | 40.33% | Wells Fargo | Stephen Baxter | $483 → $478 | Maintains | Overweight | Get Alert |
| 01/24/2025 | Buy Now | 42.39% | Cantor Fitzgerald | Sarah James | $485 → $485 | Reiterates | Overweight → Overweight | Get Alert |
| 01/24/2025 | Buy Now | 50.31% | Barclays | Andrew Mok | $501 → $512 | Maintains | Overweight | Get Alert |
| 01/06/2025 | Buy Now | 40.92% | Truist Securities | David Macdonald | $520 → $480 | Maintains | Buy | Get Alert |
| 11/18/2024 | Buy Now | 41.8% | Wells Fargo | Stephen Baxter | $495 → $483 | Maintains | Overweight | Get Alert |
| 11/05/2024 | Buy Now | 48.26% | Mizuho | Ann Hynes | $585 → $505 | Maintains | Outperform | Get Alert |
| 11/04/2024 | Buy Now | 45.32% | Wells Fargo | Stephen Baxter | $593 → $495 | Maintains | Overweight | Get Alert |
| 10/23/2024 | Buy Now | 61.76% | Morgan Stanley | Erin Wright | $643 → $551 | Maintains | Overweight | Get Alert |
| 10/22/2024 | Buy Now | 47.08% | Barclays | Andrew Mok | $622 → $501 | Maintains | Overweight | Get Alert |
| 10/21/2024 | Buy Now | 42.09% | TD Cowen | Ryan Langston | $589 → $484 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | — | Argus Research | — | — | Downgrade | Buy → Hold | Get Alert |
| 10/18/2024 | Buy Now | 62.94% | UBS | A.J. Rice | $605 → $555 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 52.66% | Truist Securities | David Macdonald | $620 → $520 | Reiterates | Buy → Buy | Get Alert |
| 10/18/2024 | Buy Now | 40.33% | RBC Capital | Ben Hendrix | $585 → $478 | Maintains | Outperform | Get Alert |
| 10/18/2024 | Buy Now | 42.39% | Cantor Fitzgerald | Sarah James | $600 → $485 | Maintains | Overweight | Get Alert |
| 10/10/2024 | Buy Now | 82.61% | Barclays | Andrew Mok | $611 → $622 | Maintains | Overweight | Get Alert |
| 10/01/2024 | Buy Now | 76.15% | Cantor Fitzgerald | Sarah James | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 76.15% | Cantor Fitzgerald | Sarah James | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 09/10/2024 | Buy Now | 76.15% | Cantor Fitzgerald | Sarah James | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 80.55% | Stephens & Co. | Scott Fidel | $615 → $615 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 76.15% | Cantor Fitzgerald | Sarah James | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 07/23/2024 | Buy Now | 76.15% | Cantor Fitzgerald | Sarah James | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 07/22/2024 | Buy Now | 74.09% | Wells Fargo | Stephen Baxter | $600 → $593 | Maintains | Overweight | Get Alert |
| 07/19/2024 | Buy Now | 72.92% | TD Cowen | Ryan Langston | $624 → $589 | Maintains | Buy | Get Alert |
| 07/18/2024 | Buy Now | 79.38% | Barclays | Andrew Mok | $621 → $611 | Maintains | Overweight | Get Alert |
| 07/18/2024 | Buy Now | 71.74% | RBC Capital | Ben Hendrix | $575 → $585 | Maintains | Outperform | Get Alert |
| 07/18/2024 | Buy Now | 55.6% | B of A Securities | Kevin Fischbeck | $646 → $530 | Downgrade | Buy → Neutral | Get Alert |
| 07/15/2024 | Buy Now | 82.02% | Truist Securities | David Macdonald | $600 → $620 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 76.15% | Cantor Fitzgerald | Sarah James | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 88.77% | Morgan Stanley | Erin Wright | → $643 | Initiates | → Overweight | Get Alert |
| 06/12/2024 | Buy Now | 76.15% | Cantor Fitzgerald | Sarah James | $600 → $600 | Reiterates | Overweight → Overweight | Get Alert |
| 06/11/2024 | Buy Now | 80.55% | Stephens & Co. | Scott Fidel | $615 → $615 | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2024 | Buy Now | 89.65% | B of A Securities | Kevin Fischbeck | $621 → $646 | Maintains | Buy | Get Alert |
| 05/30/2024 | Buy Now | 85.25% | JP Morgan | Lisa Gill | $628 → $631 | Maintains | Overweight | Get Alert |
| 05/30/2024 | Buy Now | 90.53% | Baird | Michael Ha | → $649 | Initiates | → Outperform | Get Alert |
| 04/24/2024 | Buy Now | 71.74% | Mizuho | Ann Hynes | $575 → $585 | Maintains | Buy | Get Alert |
| 04/19/2024 | Buy Now | 68.81% | RBC Capital | Ben Hendrix | $574 → $575 | Maintains | Outperform | Get Alert |
| 04/19/2024 | Buy Now | 77.62% | UBS | A.J. Rice | $585 → $605 | Maintains | Buy | Get Alert |
| 04/19/2024 | Buy Now | 76.15% | Wells Fargo | Stephen Baxter | $557 → $600 | Maintains | Overweight | Get Alert |
| 04/19/2024 | Buy Now | 76.15% | Truist Securities | David Macdonald | $580 → $600 | Reiterates | Buy → Buy | Get Alert |
| 04/19/2024 | Buy Now | 77.32% | Jefferies | David Windley | $602 → $604 | Maintains | Buy | Get Alert |
| 04/19/2024 | Buy Now | 82.31% | Barclays | Andrew Mok | $584 → $621 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | 70.28% | Cantor Fitzgerald | Sarah James | $580 → $580 | Reiterates | Overweight → Overweight | Get Alert |
| 04/08/2024 | Buy Now | 63.52% | Wells Fargo | Stephen Baxter | $561 → $557 | Maintains | Overweight | Get Alert |
| 04/04/2024 | Buy Now | 70.28% | Cantor Fitzgerald | Sarah James | $580 → $580 | Reiterates | Overweight → Overweight | Get Alert |
| 03/06/2024 | Buy Now | 71.45% | Barclays | Andrew Mok | → $584 | Initiates | → Overweight | Get Alert |
| 02/14/2024 | Buy Now | 70.28% | Cantor Fitzgerald | Sarah James | $547 → $580 | Maintains | Overweight | Get Alert |
| 02/02/2024 | Buy Now | 60.59% | Cantor Fitzgerald | Sarah James | $547 → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 01/25/2024 | Buy Now | 60.59% | Cantor Fitzgerald | Sarah James | $547 → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 01/25/2024 | Buy Now | 68.51% | RBC Capital | Ben Hendrix | $572 → $574 | Maintains | Outperform | Get Alert |
| 01/19/2024 | Buy Now | 60.59% | Cantor Fitzgerald | Sarah James | $547 → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 11/21/2023 | Buy Now | 60.59% | Cantor Fitzgerald | Sarah James | → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 11/17/2023 | Buy Now | 62.06% | JP Morgan | Lisa Gill | $569 → $552 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | 60.59% | Cantor Fitzgerald | Sarah James | → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 10/19/2023 | Buy Now | 72.33% | Morgan Stanley | Michael Ha | $585 → $587 | Maintains | Overweight | Get Alert |
| 09/14/2023 | Buy Now | 60.59% | Cantor Fitzgerald | Sarah James | → $547 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2023 | Buy Now | 71.74% | Morgan Stanley | Michael Ha | $571 → $585 | Maintains | Overweight | Get Alert |
| 07/24/2023 | Buy Now | 71.74% | TD Cowen | Gary Taylor | $564 → $585 | Maintains | Outperform | Get Alert |
| 07/20/2023 | Buy Now | 67.93% | RBC Capital | Ben Hendrix | → $572 | Reiterates | Outperform → Outperform | Get Alert |
| 07/20/2023 | Buy Now | 62.94% | Stephens & Co. | Scott Fidel | → $555 | Reiterates | Overweight → Overweight | Get Alert |
| 07/13/2023 | Buy Now | 68.81% | UBS | Kevin Caliendo | $610 → $575 | Maintains | Buy | Get Alert |
| 07/12/2023 | Buy Now | — | Wolfe Research | Justin Lake | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 07/07/2023 | Buy Now | 57.07% | JP Morgan | Lisa Gill | $572 → $535 | Maintains | Overweight | Get Alert |
| 06/20/2023 | Buy Now | 64.4% | Truist Securities | Tobey Sommer | $580 → $560 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | 67.63% | Morgan Stanley | Michael Ha | $500 → $571 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/24/2023 | Buy Now | 64.7% | Wells Fargo | Stephen Baxter | $597 → $561 | Maintains | Overweight | Get Alert |
| 04/21/2023 | Buy Now | 61.47% | Loop Capital | Joseph France | $565 → $550 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | 60.59% | Cantor Fitzgerald | Sarah James | → $547 | Initiates | → Overweight | Get Alert |
| 04/20/2023 | Buy Now | 65.58% | TD Cowen | Gary Taylor | $577 → $564 | Maintains | Outperform | Get Alert |
| 03/28/2023 | Buy Now | 67.93% | RBC Capital | Ben Hendrix | $523 → $572 | Upgrade | Sector Perform → Outperform | Get Alert |
| 03/24/2023 | Buy Now | 70.28% | Truist Securities | Tobey Sommer | $610 → $580 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | -79.16% | Wells Fargo | Stephen Baxter | $79 → $71 | Maintains | Equal-Weight | Get Alert |
| 03/08/2023 | Buy Now | 67.63% | Deutsche Bank | George Hill | $581 → $571 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | 67.93% | JP Morgan | Lisa Gill | $555 → $572 | Maintains | Overweight | Get Alert |
| 01/26/2023 | Buy Now | 53.54% | RBC Capital | Ben Hendrix | $505 → $523 | Maintains | Sector Perform | Get Alert |
| 01/26/2023 | Buy Now | 70.28% | SVB Leerink | Whit Mayo | → $580 | Reiterates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | 78.79% | Wells Fargo | Stephen Baxter | $557 → $609 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | 68.81% | Mizuho | Ann Hynes | $545 → $575 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 70.57% | Deutsche Bank | George Hill | $576 → $581 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 46.79% | Morgan Stanley | Ricky Goldwasser | $485 → $500 | Maintains | Equal-Weight | Get Alert |
| 09/09/2022 | Buy Now | 68.81% | B of A Securities | Kevin Fischbeck | $535 → $575 | Upgrade | Neutral → Buy | Get Alert |
| 08/22/2022 | Buy Now | 70.28% | SVB Leerink | Whit Mayo | $490 → $580 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/28/2022 | Buy Now | 63.52% | Wells Fargo | Stephen Baxter | $580 → $557 | Maintains | Overweight | Get Alert |
| 07/25/2022 | Buy Now | 42.39% | Morgan Stanley | Ricky Goldwasser | $533 → $485 | Maintains | Equal-Weight | Get Alert |
| 07/22/2022 | Buy Now | 43.85% | SVB Leerink | Whit Mayo | $555 → $490 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Elevance Health (ELV) stock?
The latest price target for Elevance Health (NYSE:ELV) was reported by Barclays on July 9, 2025. The analyst firm set a price target for $434.00 expecting ELV to rise to within 12 months (a possible 27.41% upside). 43 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elevance Health (ELV)?
The latest analyst rating for Elevance Health (NYSE:ELV) was provided by Barclays, and Elevance Health maintained their overweight rating.
When was the last upgrade for Elevance Health (ELV)?
The last upgrade for Elevance Health Inc happened on March 17, 2025 when Argus Research raised their price target to $450. Argus Research previously had a hold for Elevance Health Inc.
When was the last downgrade for Elevance Health (ELV)?
The last downgrade for Elevance Health Inc happened on April 15, 2025 when Baird changed their price target from $625 to $529 for Elevance Health Inc.
When is the next analyst rating going to be posted or updated for Elevance Health (ELV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevance Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevance Health was filed on July 9, 2025 so you should expect the next rating to be made available sometime around July 9, 2026.
Is the Analyst Rating Elevance Health (ELV) correct?
While ratings are subjective and will change, the latest Elevance Health (ELV) rating was a maintained with a price target of $480.00 to $434.00. The current price Elevance Health (ELV) is trading at is $340.62, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
